Eli Lilly unveiled a $3.5 billion manufacturing and device facility in Lehigh Valley, Pennsylvania dedicated to next‑generation obesity injectables, including retatrutide. The company said the plant will produce drug substance, finished drug product and associated delivery devices to support global launches and scale. The announcement underscores Lilly’s strategy to vertically integrate production for high‑demand GLP‑1 and multi‑agonist products, reduce supply‑chain risk and control device assembly for combination drug‑device therapies. Company filings and press materials highlight the plant’s role in meeting anticipated volume for retatrutide and future obesity candidates.